Blood-based liquid biopsies are the new frontier in cancer diagnosis

Guardant Health is one of the leaders in liquid biopsies for cancer diagnosis, which involve blood draws rather than invasive procedures to obtain tumor samples. Backed by more than $100 million in VC funding, the company is now processing about 1,000 samples per month. "This will lead to much more proactive treatment of cancer. It's about fighting it. With standard biopsy, you don't see cancer at its genomic level. So, we're fighting cancer blindly. We're the flashlight now. We can see the enemy. We're looking at the ebb and flow of the disease at the molecular level. This can lead to earlier diagnosis and more proactive care across every stage of the disease," said Guardant Health CEO Helmy Eltoukhy in a Q&A interview. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.